NCT05542342View on ClinicalTrials.gov

Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

May 6, 2025

Conditions
Uveal Melanoma
Interventions
DRUG

Tislelizumab

200 mg IV once every 3 weeks

DRUG

Sitravatinib Malate

100 mg orally once daily

Trial Locations (4)

28046

Hospital Universitario la Paz, Madrid

41009

Hospital Universitario Virgen de la Macarena, Seville

46014

Hospital General Universitario de Valencia, Valencia

08908

Institut Catala Oncologia (ICO) L´Hospitalet, L'Hospitalet de Llobregat

Sponsors
All Listed Sponsors
collaborator

Mirati Therapeutics Inc.

INDUSTRY

collaborator

BeiGene

INDUSTRY

lead

Grupo Español Multidisciplinar de Melanoma

OTHER

NCT05542342 - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. | Biotech Hunter | Biotech Hunter